JYP0015

JYP0015 is a small-molecule drug developed by Guangzhou JOYO Pharma. Its target is KRAS (the sponsor names KRAS, NRAS, HRAS (pan-RAS)). The sponsor states: An orally bioavailable pan-RAS inhibitor designed to selectively target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS and HRAS isoforms, including mutations at codons 12, 13, 61, 117 and 146. ClinicalTrials.gov describes the intervention as: JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer. The largest, NCT06895031, plans to enrol 210 participants with primary completion expected 2026-03-30. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.